Wedbush raised the firm’s price target on Aprea Therapeutics to $11 from $9 and keeps an Outperform rating on the shares after the company reported Q4 financial results and shared updates for its ATR and WEE1 inhibitor programs. The firm notes Aprea continues to make progress in the dose-escalation study of ATR inhibitor, with early efficacy data on track to be shared in the second half of 2024. Additionally, updated data from part 1 of the study will be shared at the AACR meeting next month as part of a poster presentation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APRE:
- Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
- Aprea Therapeutics sees cash runway into 3Q25
- Aprea Therapeutics reports Q4 EPS (92c), consensus (77c)
- APRE Upcoming Earnings Report: What to Expect?
- Biotech Alert: Searches spiking for these stocks today
